Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Salix Pharmaceuticals



) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.6%. By the end of trading, Salix Pharmaceuticals fell $1.32 (-1.9%) to $68.32 on average volume. Throughout the day, 652,672 shares of Salix Pharmaceuticals exchanged hands as compared to its average daily volume of 763,600 shares. The stock ranged in price between $67.49-$69.99 after having opened the day at $69.74 as compared to the previous trading day's close of $69.64. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 43.4%,

Oxygen Biotherapeutics



), down 5.0%,

Inovio Pharmaceuticals



Scroll to Continue

TheStreet Recommends

), down 4.8% and




), down 4.3%.

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices used in the treatment of various gastrointestinal diseases in the United States. Salix Pharmaceuticals has a market cap of $4.2 billion and is part of the health care sector. Shares are up 67.7% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Salix Pharmaceuticals

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front,

Ambit Biosciences



), up 25.5%,

Horizon Pharma



), up 20.8%,

GW Pharmaceuticals PLC ADR



), up 15.4% and

Ocera Therapeutics



), up 13.0% , were all gainers within the drugs industry with

Biogen Idec



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.